In today's ACT Brief, we examine leadership instability and regulatory uncertainty during Makary's FDA tenure, how lived ...
FDA Commissioner Marty Makary, MD, MPH, resigned Tuesday, according to The Associated Press, just 13 months after being ...
In today's ACT Brief, we examine cost models for imaging infrastructure in clinical trials, how community relationships ...
A multi-stakeholder tabletop exercise evaluated SSDC integration into pragmatic trials, emphasizing fit-for-purpose safety ...
In this Q&A, Mark Freitas, managing director and life sciences practice lead at Alvarez & Marsal, discusses how clinical ...
Week-24 TRuE-AD4 outcomes with ruxolitinib 1.5% cream showed 84.3% EASI75 and 70.6% IGA Treatment Success among completers ...
On the heels of FDA’s clearance, the company plans to begin a Phase Ib/IIa trial evaluating CK0802 in patients who have ...
As the use of digital tools continues to expand within clinical research, effective data management for eCOA systems is more important than ever. From initial design and system setup to ongoing ...
A phase 3 trial evaluating Moderna’s investigational seasonal influenza vaccine, mRNA-1010, found the messenger RNA ...
LUCENT-3 trial open-label extension data show 63.5% of adults with ulcerative colitis administered mirikizumab (Omvoh) who ...
Guselkumab (Tremfya) showed higher 24-week fistula remission than placebo in adults with perianal fistulizing Crohn disease.
Execution instability often originates in strategy timing rather than study conduct, which sponsors can correct by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results